Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980–2009

References

• Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut 1962;8:65–66.
   PubMedGoogle Scholar
• Arkesteijn GJ, Martens AC, Hagenbeek A. Bivariate flow karyotyping in human Philadelphia-positive chronic myelocytic leukemia. Blood 1988;72:282–286.
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, et al. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 1995;85:2705–2710.
   PubMed Web of Science ®Google Scholar
• Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists’ Collaborative Group. J Natl Cancer Inst 1997;89:1616–1620.
   Google Scholar
• Clift R, Appelbaum F, Thomas E. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993;82:1954–1956.
   PubMed Web of Science ®Google Scholar
• Moreb J, Johnson T, Kubilis P, et al. Improved survival of patients with chronic myelogenous leukemia undergoing allogeneic bone marrow transplantation. Am J Hematol 1995;50:304–306.
   PubMed Web of Science ®Google Scholar
• Druker B. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. Semin Hematol 2001; 38:9–14.
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase. Cancer 2003;98:2636–2642.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: an evidence-based review. Core Evid 2010;4:207–213.
   PubMedGoogle Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Rosti G, Beris P, et al. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Rev Hematol 2010;3:665–673.
   PubMed Web of Science ®Google Scholar
• Percy C, Van Holten V, Muir C. International Classification of Diseases for Oncology. 2nd ed. Geneva: World Health Organization; 1990.
   Google Scholar
• Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
   Google Scholar
• Bouyer J, Hémon D, Cordier S, et al. Epidémiologie – principes et méthodes quantitatives. Paris: Éditions Inserm; 1993.
   Google Scholar
• Estimation de la population au 1er janvier par région (1990–2010), département (1990–2009), sexe et âge (quinquennal, classes d’âge). Paris: Institut national de la statistique et des études économiques; 2012. Available from: www.insee.fr/fr/themes/detail.asp?ref_id = e stim-pop&reg_id = 99
   Google Scholar
• Waterhouse J., Correa P, Muir C, et al., editors. Cancer incidence in five continents, Vol. III. Lyon: IARC; 1976.
   Google Scholar
• Segi M. Cancer mortality for selected sites in 24 countries (1950-57). Department of Public Health, Tohoku University of Medicine, Sendai, Japan. 1960.
   Google Scholar
• Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Available from: www.mortality.org; www.humanmortality.de
   Google Scholar
• Pohar M, Stare J. Relative survival analysis in R. Comput Methods Programs Biomed 2006;81:272–278.
   PubMed Web of Science ®Google Scholar
• Corm S, Roche L, Micol J-B, et al. Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990–2007: a population study. Blood 2011;118:4331–4337.
   PubMed Web of Science ®Google Scholar
• Phekoo KJ, Richards MA, Møller H, et al. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 2006;91:1400–1404.
   PubMed Web of Science ®Google Scholar
• Osca-Gelis G, Puig-Vives M, Saez M, et al. Population- based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica 2013;98:e95–e97.
   PubMed Web of Science ®Google Scholar
• Visser O, Trama A, Maynadié M, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012;48:3257–3266.
   PubMed Web of Science ®Google Scholar
• Maynadié M, Girodon F, Manivet-Janoray I, et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Côte d’Or (Burgundy, France). Haematologica 2011;96:55–61.
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724–3734.
   PubMed Web of Science ®Google Scholar
• Monnereau A, Troussard X, Belot A, et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer 2013;132:2378–2387.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119: 1981–1987.
   PubMed Web of Science ®Google Scholar
• Osca-Gelis G, Puig-Vives M, Saez M, et al. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study. Leuk Lymphoma 2014 Aug 18. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica 2008;93:1544–1549.
   PubMed Web of Science ®Google Scholar
• Gugliotta G, Castagnetti F, Palandri F, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011; 117:5591–5599.
   PubMed Web of Science ®Google Scholar
• Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011;29:2514–2520.
   PubMed Web of Science ®Google Scholar
• Wiggins CL, Harlan LC, Nelson HE, et al. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med 2010;123:764.e1–9.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118:4554–4560.
   PubMed Web of Science ®Google Scholar
• Yeung DT, Hughes TP. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Crit Rev Oncog 2012;17:17–30.
   PubMedGoogle Scholar
• Verma D, Kantarjian H, Strom SS, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 2011;118:4353–4358.
   PubMed Web of Science ®Google Scholar
• Voglova J, Muzik J, Faber E, et al. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 2011; 58:256–262.
   PubMed Web of Science ®Google Scholar
• Rebora P, Czene K, Antolini L, et al. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol 2010;172:1028–1033.
   PubMed Web of Science ®Google Scholar
• Chihara D, Ito H, Matsuda T, et al. Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S. Oncologist 2012;17:1547–1550.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Onida F, Ball G, Kantarjian HM, et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 2002;95: 1673–1684.
   PubMed Web of Science ®Google Scholar
• Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV. Blood 2011;118:6760–6768.
   PubMed Web of Science ®Google Scholar